Half of Ovarian Cancer Patients Respond to Quisinostat Combo Therapy, Phase 2 Clinical Trial Shows

Half of Ovarian Cancer Patients Respond to Quisinostat Combo Therapy, Phase 2 Clinical Trial Shows
Half of patients with advanced ovarian cancer responded either fully or partially to a combination of quisinostat, Taxol (paclitaxel) and Paraplatin (carboplatin), according to a Phase 2 clinical trial. The trial (NCT02948075) dealt with patients with metastatic or advanced ovarian cancer whose cancer had progressed after first-line platinum and Taxol-based chemotherapy. The regression rate of

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *